Stocks lower Friday. Movers: Palantir, Applied Materials, Ulta Beauty
Here are the stocks making the biggest market moves midday.
Trump taps ex-SEC chairman for top Manhattan prosecutor role as crypto cases may wind down
The office, known for high-profile crypto cases, will allocate fewer resources to pursuing crypto firms in Trump's second term, a report says.
Fed's Goolsbee sees another 125 bps of rate cuts by end-2025
"I think we are going to be looking at rates coming down over the next year along the line the dot-plot said," Goolsbee told Bloomberg TV, referring to Fed projections released in September that depict the rate-path forecasts of the Fed's 19 policymakers as dots on a chart. The median view of that dot plot was for the Fed policy rate to end this year at 4.4%, a quarter of a percentage point below where it is today, and to be 3.4% by the end of next year.
Warren Buffett dumped Bank of America, but the stock may boom under Trump
Bank stocks surged broadly on Trump's win, with investors anticipating deregulation and pent-up M&A demand to be unlocked.
Trump's Win, Economic Challenges Lead to Tougher Outlook for Renewable Energy Stocks: Morgan Stanley
The recent U.S. presidential election results, including a Republican sweep, have raised questions about the future of renewable energy under President-elect Donald Trump’s leadership. Morgan Stanley’s report evaluates the economic impact on renewables under various policy scenarios and its effects on earnings. The analyst has adjusted its view on the clean tech industry to “In-Line” from “Attractive.” Also Read: Solar, Renewables Stocks Crash After Trump Win: Should You Buy Now At Cheap Valuati
Starbucks (NASDAQ:SBUX) Still Has Room for Improvement Before Buying
“The customer is always right” is a credo that is often used and applies especially to consumer-facing businesses like Starbucks (SBUX). Throughout its history, the coffee franchise’s focus on the customer experience and product quality has paid off remarkably. After all, the Starbucks brand is estimated to be worth $60.7 billion, making it the 15th most valuable brand in the world. But even with all of this success, the company still has immense room for improvement. Indeed, Starbucks’ sales ha
Nvidia results in focus as stock market's election boost stalls
Nvidia Corp's results in the coming week could guide the U.S. stock market on its next path, as investors turn their focus to the technology sector and artificial intelligence trade after an election-fueled rally stalled. A nearly 800% run in shares of Nvidia over the past two years, driven by its gold standard AI business, has propelled the semiconductor company to the world's top spot by market value. That heft gives Nvidia huge sway in market benchmarks, such as the S&P 500 and Nasdaq 100, while its results on Nov. 20 will also be a gauge for the market's appetite for tech stocks, the AI trade and sentiment for equities broadly, investors said.
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?
On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa (PEG-IFNα), in participants with chronic hepatitis B. Chronic hepatitis B (CHB) is a long-lasting, inflammatory liver disease caused by the hepatitis B virus (HBV). The World Health Organization estimates that 254 million people live with CHB, and an estimated 1.1 million yearly deaths
The Many Ways Crypto Won in This Election
The dust is starting to clear on the election and no one won bigger than crypto. Aubrey Strobel looks at how the new Trump Administration could help the industry moving forward.
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
On Friday, Eyenovia, Inc. (NASDAQ:EYEN) stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company’s Optejet dispensing platform pediatric progressive myopia. Progressive myopia is a type of nearsightedness that worsens over time due to the eyeball growing too long. The company said that an independent Data Review Committee (DRC) reviewed the CHAPERONE data and found that the trial is not meeting